Efficacy of Caregiver Training Program in Enhancing Caregiver and Patient Outcomes
Launched by MAPHABIT, INC. · Sep 1, 2022
Trial Information
Current as of October 25, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new training program designed to help caregivers of individuals with Alzheimer's disease or related dementias. The program uses a system called MapHabit, which provides visual tools to help improve the daily care and independence of patients. The trial will involve 50 pairs of patients and their primary caregivers, who will be split into two groups: one group will use the MapHabit system alone, while the other group will use it along with the caregiver training program. The goal is to see if adding this training helps reduce the stress and challenges caregivers face while caring for their loved ones.
To be eligible for this trial, participants must have a diagnosis of mild to moderate Alzheimer's disease or related dementia, and their caregiver should be the main person providing daily support. Both the patient and caregiver need to be proficient in English. If you join the study, you can expect to participate for six months and receive support through the MapHabit system, which aims to enhance both your experience and the quality of care provided. This study is not yet recruiting participants, but it represents an important step in improving the lives of caregivers and those they care for.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Individual diagnosed with Alzheimer's disease or other related dementia (ADRD) in their mild to moderate stage of impairment
- • Participating caregiver of individual with dementia must be the primary caregiver
- • Proficient in English
- Exclusion Criteria:
- • Individual not diagnosed with ADRD
- • Participating caregiver of individual with dementia is NOT the primary caregiver
- • Not proficient in English
About Maphabit, Inc.
Maphabit, Inc. is a clinical trial sponsor dedicated to advancing healthcare through innovative research and development. Specializing in the design and management of clinical studies, Maphabit focuses on delivering effective solutions in the realms of pharmaceuticals and medical devices. With a commitment to adhering to the highest ethical standards and regulatory guidelines, the company collaborates with healthcare professionals and research institutions to ensure the integrity and reliability of its clinical trials. Maphabit strives to enhance patient outcomes and contribute to the evolving landscape of medical science through rigorous data analysis and a patient-centered approach.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Atlanta, Georgia, United States
Patients applied
Trial Officials
Stuart Zola
Principal Investigator
MapHabit, Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials